title: [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
authors.affiliation: Service de Néphrologie, CHUV Lausanne. michel.burnier@chuv.ch
authors.forename: M
authors.initials: M
authors.lastname: Burnier
authors.forename: B
authors.initials: B
authors.lastname: Waeber
authors.forename: O
authors.initials: O
authors.lastname: Hess
authors.forename: T
authors.initials: T
authors.lastname: Lüscher
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D017257:Ramipril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan